Navigation Links
Stem cells reach standard for use in drug development
Date:6/11/2013

Drug development for a range of conditions could be improved with stem cell technology that helps doctors predict the safety and the effectiveness of potential treatments.

Medical Research Council scientists at the University of Edinburgh have been able to generate cells in the laboratory that reach the gold standard required by the pharmaceutical industry to test drug safety.

The researchers used stem cell technology to generate liver cells which help our bodies to process drugs.

They found that the cells were equally effective, reaching the same standard, as cells from human liver tissue currently used to assess drug safety.

These human cells used in drug testing are in short supply and vary considerably due to different donors. As a result they are not an ideal source for drug development.

The stem cell based technique developed in Edinburgh, addresses these issues by offering a renewable production of uniform liver cells in the laboratory.

Dr David Hay of the Medical Research Council (MRC) Centre for Regenerative Medicine at the University of Edinburgh, said: "Differing genetic information plays a key role in how patients' livers process drugs. We are now able to efficiently produce human liver cells in the laboratory from different people which model the functional differences in human genetics."

Researchers hope to generate liver cells, containing different DNA to reflect the genetic variations in metabolism found in the population that could be used to help identify differences in response among patients to certain drugs. The laboratory-generated liver cells could also be used to screen certain drugs that need close monitoring, to optimise patient treatment.

Scientists are working with Edinburgh BioQuarter, with a view to forming a spin-out company to commercialise the research.


'/>"/>

Contact: Tara Womersley
tara.womersley@ed.ac.uk
44-131-650-9836
University of Edinburgh
Source:Eurekalert

Page: 1

Related biology news :

1. How cells get a skeleton
2. First dual-action compound kills cancer cells, stops them from spreading
3. Down syndrome neurons grown from stem cells show signature problems
4. Keeping stem cells strong
5. MU researchers develop radioactive nanoparticles that target cancer cells
6. Insight into the dazzling impact of insulin in cells
7. The compound in the Mediterranean diet that makes cancer cells mortal
8. SUMO wrestling cells reveal new protective mechanism target for stroke
9. Herpes infections: Natural killer cells activate hematopoiesis
10. Cells must use their brakes moderately for effective speed control
11. Newly described type of immune cell and T cells share similar path to maturity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
Breaking Biology News(10 mins):
(Date:7/20/2017)... ... ... VIC Technology Venture Development™ (VIC™), is pleased to announce that James ... to strengthen and diversify VIC’s board. , "We are excited to have Jamie join ... business executive with a broad range of experience directly relevant to VIC as we ...
(Date:7/20/2017)... ... 2017 , ... Crucial Data Solutions (CDS) is excited to ... unified. TrialKit, a native mobile app, empowers investigators and clinicians to build, deploy, ... mobile devices. With TrialKit, clinical researchers can utilize Core Motion technologies and Apple’s ...
(Date:7/18/2017)... ... July 18, 2017 , ... G-CON today announced that ... Office for its Patent Applications 14/858,857 and 13/669,785 both entitled Modular, Self-Contained, Mobile ... further expand the protection of G-CON’s R&D investments and validate the G-CON platform ...
(Date:7/17/2017)... ... July 17, 2017 , ... Whitehouse Laboratories is excited ... encompass the full series of ISO 80369 standard test procedures. The ISO 80369 ... and drug delivery systems. With this recent expansion, Whitehouse Labs becomes one of ...
Breaking Biology Technology: